Macomics expands in Edinburgh, appoints Professor Paul Crocker to SAB

Macomics Ltd, a leader in macrophage drug discovery, continues its growth trajectory with expansion in Edinburgh into dedicated facilities within the Roslin Innovation Centre. The company has also announced the appointment of Professor Paul Crocker FRSE, Emeritus Professor of Glycoimmunology, University of Dundee to its Scientific Advisory Board (SAB).

Macomics’ operations are located in Edinburgh and Cambridge, two major hubs of life science research in the UK with R&D teams split 50:50 across both sites. To accommodate expansion and to be co-located in an entrepreneurial centre of scientific excellence, Macomics has recently moved to dedicated laboratories in the Roslin Innovation Centre. The new facilities are 50% larger than its founding base at Edinburgh University.

“The Roslin Innovation Centre Easter Bush Campus provides a dynamic and vibrant working environment with world-class facilities equipped with the latest technologies” Stephen Myatt, CEO of Macomics.

Macomics, the brainchild of world-recognised experts in macrophage biology, the late Prof Jefferey Pollard and Macomics VP immunology and co-founder, Dr Luca Cassetta, is exploiting the potential of macrophage-based approaches to develop novel precision medicines to target disease specific macrophage biology. Whilst it is the only human drug discovery company at the incubator, other companies exploiting macrophage biology for animal health provide for a productive scientific exchange.

Macomics’ ENIGMAC macrophage drug discovery platform integrates large volume human data sets, custom cell models, and proprietary human macrophage genome editing capability to discover novel targets and unlock disease specific target biology. Macrophages (TAMs) are often the most abundant immune cell many types of cancer and modulating TAMs can enhance the body’s ability to fight cancer.

Maximising on local expertise and connections, Professor Paul Crocker FRSE, Emeritus Professor of Glycoimmunology, University of Dundee has joined Macomics’ SAB. Prof. Crocker is a recognised expert in the understanding how immune cells utilise host glycans to regulate immune and inflammatory responses and translating this to human disease. 

Dr Luca Cassetta, VP immunology and co-founder of Macomics said, “It is a pleasure to welcome Paul to our SAB, having been local academic colleagues over many years. Our SAB is very International but having Paul’s expertise on our doorstep in Scotland and his knowledge of glycoimmunology and immune and inflammatory responses adds important expertise as we advance our macrophage targeting drug discovery programmes.”


More news and updates 

DLRC achieves King’s Award for Enterprise in International Trade

DLRC Ltd has been honoured with the King’s Award for Enterprise, recognising its outstanding performance in international trade. This places DLRC among a select group of only 252 organisations in the UK to receive this prestigious award.

Optibrium partners with FMC Corporation to transform agrochemical discovery

Optibrium’s AI-powered discovery platform Cerella™ chosen by FMC to accelerate its agrochemical discovery pipeline.

Touchlight Genetics and NPL awarded grant to develop novel gene-length single-stranded genome editing template

Touchlight Genetics, in partnership with the National Physical Laboratory (NPL) have secured funding from Innovate UK under their Innovative Technologies: Nucleic Acid Medicines Manufacture, Round 2 call. 

PrecisionLife and Metrodora Institute launch clinical trials to accelerate treatment of ME/CFS and long Covid patients

Up to 1,000 patients being recruited into targeted precision medicine clinical trials expected to readout results as early as this year; trials are designed to provide validation of safety and effectiveness for novel diagnostics and innovative clinical care pathways in ME/CFS and Long Covid.

European Life Sciences sector primed for growth in 2024 driving real estate demand and investment opportunities

The European Life Science sector has been marked by strong growth and resilience in recent years and is set for significant expansion in 2024, driven by new medical treatments and both private and public funding according to JLL’s Life Sciences Industry & Real Estate Perspective report.

Ingenza expanding codABLE® gene design algorithm to aid recombinant protein production in yeast

Scottish CRDMO Ingenza has secured innovation funding to adapt its codABLE® machine learning platform to precisely control recombinant protein expression in the industrial yeast Pichia pastoris. This game-changing project will accelerate the development of therapeutics, enzymes and other proteins by harnessing machine learning to fine-tune codon usage, ensuring seamless compatibility with the production host and maximising production yields.

Arecor and Medtronic Diabetes establish collaboration to develop novel thermostable insulin for implantable pump delivery

Medtronic to fund Arecor’s development of Arestat™ enabled novel, high concentration, thermostable insulin, specifically tailored for use in combination with a next-generation implantable pump

Infinitopes secures £12.8 million seed financing to enhance its Precision ImmunomicsTM antigen discovery technologies

Infinitopes Precision Immunomics, an integrated cancer biotech combining world-leading platforms in precision antigen discovery with vaccine vectors capable of durably stimulating protective immune responses, today announced the completion of a £12.8 million seed funding round led by Octopus Ventures.

Business Opportunity: Advance your workforce with a Bioscience Degree Apprenticeship

Manchester Metropolitan University have opened applications for the Laboratory Science Degree Apprenticeships in Bioscience. New cohorts are set to begin in September.

Poolbeg Pharma plc announces exclusive option agreement to acquire Orphan Drug Candidate for Behçet's Disease

Poolbeg Pharma plc announces that it has entered into an exclusive 12-month option agreement with Silk Road Therapeutics Inc, for a nominal fee, to acquire a novel topical muco-adherent formulation of Pentoxifylline (tPTX) for the treatment of oral ulcers in patient's suffering from Behçet's Disease.


More within